ClinicalTrials.gg
CompletedNCT00946153Updated Feb 1, 2019Results posted

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

A Phase 1/2 interventional study of Lenvatinib in Hepatocellular Carcinoma, sponsored by Eisai Co., Ltd.. Completed at 12 sites in 2 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Eisai Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Enrollment
36th of 121
66 · median 48
Started
2009
the only one that year
Phase 1/2
9 of 121
3 open now
Registered
1st of 121
by date
Lead sponsor
4 of 121
Eisai Co., Ltd.

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 36th largest by enrollment, is the only one that started in 2009, is one of 9 in phase 1/2, and was the 1st registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is administered continually once daily in participants with advanced hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Carcinoma
  • Hepatocellular
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologically or clinically confirmed diagnosis of advanced HCC.
  2. -Performance Status (ECOG-PS): 0-1.
  3. Adequate laboratory values/organ function tests.

Exclusion criteria

Exclusion criteria:

  1. Simultaneous or metachronous cancers.
  2. Pericardial, ascites, or pleural effusion requiring drainage.
  3. /meningeal carcinomatosis presenting clinical symptoms or requiring treatment.
  4. Malabsorption syndrome.
  5. Artery-portal vein shunt or artery-vein shunt preventing proper diagnosis of tumor.
  6. Use of drugs known to inhibit cytochrome P3A4.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Lenvatinib

    Drug: Lenvatinib

Interventions

  • In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.

    Also known as: E7080

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib

    The MTD was defined as the highest dose level at which no more than 1 of 6 participants had a dose limiting toxicities (DLT). DLT was defined as any of the following events: grade 4 or higher hematologic toxicity or grade 3 thrombocytopenia that required blood transfusion, grade 3 or higher nonhematologic toxicity, grade 4 hypertension uncontrolled by antihypertensive drug(s), aspartate aminotransferase/alanine aminotransferase (AST/ALT) greater than (\>) 10.0\*upper limit of normal (ULN), proteinuria 4+ by urine dipstick, proteinuria 3+ by urine dipstick was to be monitored by 24-hour urine collection, proteinuria \>3.5 gram (g) for 24 hours, diarrhea/vomiting/nausea of grade 3 or higher that was uncontrollable despite maximal supportive therapies and abnormal clinical laboratory values that required no treatment, grade 3 proteinuria by dipstick, diarrhea/vomiting/nausea that was managed with supportive therapies were not considered as DLT.

    Time frame: Up to 28 days (Cycle1)

  2. Phase 2: Time to Progression (TTP) by Independent Review Assessment

    TTP was defined as the time from the date of registration to the date when progressive disease (PD) was first confirmed. PD was evaluated according to modified response evaluation criteria in solid tumors (mRECIST) by an independent imaging review. PD was defined as at least a 20 percent (%) increase in the sum of long diameter (LD) of target lesions as compared with the smallest sum of LD and the increase of LD was at least 5 millimeter (mm) (including new lesions).

    Time frame: From day of registration to the day when PD was first confirmed (approximately up to 6.1 years)

Secondary outcomes

  1. Phase 1: Best Overall Response (BOR) of Lenvatinib by Investigator Assessment

    BOR was performed using RECIST1.1 and was measured as complete response (CR) defined as when an overall response of CR was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of CR was confirmed and the BOR established as CR was regarded as the "CR confirmed date), partial response (PR) defined as when the overall response of PR or better (CR or PR) was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of PR was confirmed and the BOR established as PR will be regarded as the "PR confirmed date), PD defined as when the BOR was neither CR, PR, or stable disease (SD), and the overall response was PD, SD defined as when the BOR obtained was neither CR nor PR, but no PD from the initial administration to the end of Cycle 2 and the overall response of SD or better occurred at least once and not evaluable (NE) was when the overall response was NE in all cases.

    Time frame: Every 8 weeks (approximately up to 18.4 months)

  2. Phase 1: Objective Response Rate (ORR) by Investigator Assessment

    ORR was defined as the percentage of participants who achieved a tumor response measured by RECIST 1.1 of CR defined as disappearance of all target lesions (a short diameter is less than (\<)10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.

    Time frame: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)

  3. Phase 1: Disease Control Rate (DCR) by Investigator Assessment

    DCR was measured by RECIST 1.1 and defined as CR which was defined as disappearance of all target lesions (a short diameter was \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.

    Time frame: Up to Week 16

  4. Phase 2: Progression-free Survival (PFS) by Independent Review Assessment

    PFS was defined as the time from the date of registration until the date when PD was first confirmed or death (whichever occurred first) as determined by mRECIST and PD was defined as at least a 20% increase in the sum of long diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.

    Time frame: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)

  5. Phase 2: Objective Response Rate (ORR) by Independent Review Assessment

    ORR was defined as the percentage of participants who achieved a tumor response measured by mRECIST of CR defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.

    Time frame: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)

  6. Phase 2: Disease Control Rate (DCR) by Independent Review Assessment

    DCR was measured by mRECIST and defined as CR which was defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.

    Time frame: Weeks 8 and 16

  7. Phase 2: Overall Survival (OS)

    OS was defined as the time from the date of registration until the date of death.

    Time frame: From day of registration to the day of death (approximately 6.1 years)

07

Results

Posted Feb 1, 2019

Participant flow

Participants took part in the study at 12 sites in Japan and 2 sites in South Korea from 24 Jul 2009 to 13 Aug 2015.

Phase 1
Participant flow — Phase 1
MilestonePhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mg
Started63650
Completed63650
Not completed00000
Phase 2
Participant flow — Phase 2
MilestonePhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mg
Started000046
Completed000033
Not completed000013
Withdrew: Adverse event00006
Withdrew: Need more reduction of dose00002
Withdrew: Physician decision00001
Withdrew: 14 days washout for recovery due to ae00004

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD) of Lenvatinib

The MTD was defined as the highest dose level at which no more than 1 of 6 participants had a dose limiting toxicities (DLT). DLT was defined as any of the following events: grade 4 or higher hematologic toxicity or grade 3 thrombocytopenia that required blood transfusion, grade 3 or higher nonhematologic toxicity, grade 4 hypertension uncontrolled by antihypertensive drug(s), aspartate aminotransferase/alanine aminotransferase (AST/ALT) greater than (\>) 10.0\*upper limit of normal (ULN), proteinuria 4+ by urine dipstick, proteinuria 3+ by urine dipstick was to be monitored by 24-hour urine collection, proteinuria \>3.5 gram (g) for 24 hours, diarrhea/vomiting/nausea of grade 3 or higher that was uncontrollable despite maximal supportive therapies and abnormal clinical laboratory values that required no treatment, grade 3 proteinuria by dipstick, diarrhea/vomiting/nausea that was managed with supportive therapies were not considered as DLT.

Time frame:
Up to 28 days (Cycle1)
Reported as:
Number · milligram (mg)
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib
milligram (mg)Phase 1: Group 1: Levatinib 12 or 16 mg (CP Score 5 or 6)Phase 1: Group 2: Lenvatinib 8 or 12 mg (CP Score 7 or 8)
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib128
PrimaryPhase 2: Time to Progression (TTP) by Independent Review Assessment

TTP was defined as the time from the date of registration to the date when progressive disease (PD) was first confirmed. PD was evaluated according to modified response evaluation criteria in solid tumors (mRECIST) by an independent imaging review. PD was defined as at least a 20 percent (%) increase in the sum of long diameter (LD) of target lesions as compared with the smallest sum of LD and the increase of LD was at least 5 millimeter (mm) (including new lesions).

Time frame:
From day of registration to the day when PD was first confirmed (approximately up to 6.1 years)
Reported as:
Median · months
Phase 2: Time to Progression (TTP) by Independent Review Assessment
monthsPhase 2 : Lenvatinib :12 mg
Phase 2: Time to Progression (TTP) by Independent Review Assessment7.40 (5.50 to 9.40)
SecondaryPhase 1: Best Overall Response (BOR) of Lenvatinib by Investigator Assessment

BOR was performed using RECIST1.1 and was measured as complete response (CR) defined as when an overall response of CR was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of CR was confirmed and the BOR established as CR was regarded as the "CR confirmed date), partial response (PR) defined as when the overall response of PR or better (CR or PR) was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of PR was confirmed and the BOR established as PR will be regarded as the "PR confirmed date), PD defined as when the BOR was neither CR, PR, or stable disease (SD), and the overall response was PD, SD defined as when the BOR obtained was neither CR nor PR, but no PD from the initial administration to the end of Cycle 2 and the overall response of SD or better occurred at least once and not evaluable (NE) was when the overall response was NE in all cases.

Time frame:
Every 8 weeks (approximately up to 18.4 months)
Reported as:
Count of participants · Participants
Phase 1: Best Overall Response (BOR) of Lenvatinib by Investigator Assessment
ParticipantsPhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mg
Complete Response0000
Partial Response1110
Stable Disease2242
Progressive Disease2013
Not Evaluable1000
SecondaryPhase 1: Objective Response Rate (ORR) by Investigator Assessment

ORR was defined as the percentage of participants who achieved a tumor response measured by RECIST 1.1 of CR defined as disappearance of all target lesions (a short diameter is less than (\<)10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.

Time frame:
From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Reported as:
Number · percentage of participants
Phase 1: Objective Response Rate (ORR) by Investigator Assessment
percentage of participantsPhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mg
Phase 1: Objective Response Rate (ORR) by Investigator Assessment16.733.316.70
SecondaryPhase 1: Disease Control Rate (DCR) by Investigator Assessment

DCR was measured by RECIST 1.1 and defined as CR which was defined as disappearance of all target lesions (a short diameter was \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.

Time frame:
Up to Week 16
Reported as:
Number · percentage of participants
Phase 1: Disease Control Rate (DCR) by Investigator Assessment
percentage of participantsPhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mg
Phase 1: Disease Control Rate (DCR) by Investigator Assessment5010083.340.0
SecondaryPhase 2: Progression-free Survival (PFS) by Independent Review Assessment

PFS was defined as the time from the date of registration until the date when PD was first confirmed or death (whichever occurred first) as determined by mRECIST and PD was defined as at least a 20% increase in the sum of long diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.

Time frame:
From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Reported as:
Median · months
Phase 2: Progression-free Survival (PFS) by Independent Review Assessment
monthsPhase 2 : Lenvatinib :12 mg
Phase 2: Progression-free Survival (PFS) by Independent Review Assessment7.40 (5.50 to 9.40)
SecondaryPhase 2: Objective Response Rate (ORR) by Independent Review Assessment

ORR was defined as the percentage of participants who achieved a tumor response measured by mRECIST of CR defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.

Time frame:
From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Reported as:
Number · percentage of participants
Phase 2: Objective Response Rate (ORR) by Independent Review Assessment
percentage of participantsPhase 2 : Lenvatinib :12 mg
Phase 2: Objective Response Rate (ORR) by Independent Review Assessment41.5 (26.3 to 57.9)
SecondaryPhase 2: Disease Control Rate (DCR) by Independent Review Assessment

DCR was measured by mRECIST and defined as CR which was defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.

Time frame:
Weeks 8 and 16
Reported as:
Number · percentage of participant
Phase 2: Disease Control Rate (DCR) by Independent Review Assessment
percentage of participantPhase 2 : Lenvatinib :12 mg
Week 887.8 (73.8 to 95.9)
Week 1678.0 (62.4 to 89.4)
SecondaryPhase 2: Overall Survival (OS)

OS was defined as the time from the date of registration until the date of death.

Time frame:
From day of registration to the day of death (approximately 6.1 years)
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2 : Lenvatinib :12 mg
Phase 2: Overall Survival (OS)18.30 (12.70 to 25.10)

Adverse events

Collected over From start of study drug administration until approximately up to 6.1 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Group 1: Lenvatinib: 12 mg0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase 1: Group 1: Lenvatinib: 16 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase 1: Group 2: Lenvatinib: 8 mg1/6 (16.7%)3/6 (50%)6/6 (100%)
Phase 1: Group 2: Lenvatinib: 12 mg1/5 (20%)3/5 (60%)5/5 (100%)
Phase 2: Lenvatinib: 12 mg32/46 (69.6%)22/46 (47.8%)46/46 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mg
PneumoniaInfections and infestations0/61/30/60/51/46
Hepatic encephalopathyNervous system disorders0/61/30/61/55/46
Hepatic failureHepatobiliary disorders0/60/30/61/50/46
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/31/61/50/46
HaematemesisGastrointestinal disorders0/60/31/60/50/46
HyperbilirubinaemiaHepatobiliary disorders1/60/31/60/50/46
Biliary tract infectionInfections and infestations1/60/30/60/50/46
Renal impairmentRenal and urinary disorders0/60/30/60/53/46
Oedema peripheralGeneral disorders0/60/30/60/52/46
Acute coronary syndromeCardiac disorders0/60/30/60/51/46
Most frequent other events
Showing 10 of 214
Most frequent other events
EventPhase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mg
ConstipationGastrointestinal disorders2/63/30/60/519/46
DiarrhoeaGastrointestinal disorders6/63/36/63/520/46
NauseaGastrointestinal disorders2/63/33/64/516/46
FatigueGeneral disorders5/63/35/65/525/46
Decreased appetiteMetabolism and nutrition disorders6/62/33/65/528/46
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders5/63/33/62/530/46
HypertensionVascular disorders5/63/33/64/535/46
VomitingGastrointestinal disorders3/63/32/62/511/46
Oedema peripheralGeneral disorders0/62/35/61/516/46
Blood thyroid stimulating hormone increasedInvestigations5/61/32/61/512/46

Baseline characteristics

All participants who received at least 1 dose of lenvatinib, and had at least 1 post baseline efficacy evaluation.

Age, Customized
Age, Customized(Participants)Phase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mgTotal
>=37 years and <=80 years63654666
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mgTotal
Female12001316
Male51653350
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Group 1: Lenvatinib: 12 mgPhase 1: Group 1: Lenvatinib: 16 mgPhase 1: Group 2: Lenvatinib: 8 mgPhase 1: Group 2: Lenvatinib: 12 mgPhase 2: Lenvatinib: 12 mgTotal
American Indian or Alaska Native000000
Asian63654666
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
08

Study locations

12 sites
  • Kashiwa-shi, Chiba, Japan
  • Kurume-shi, Fukuoka, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Kawasaki-shi, Kanagawa, Japan
  • Osaka-shi, Osaka, Japan
  • Osakasayama-shi, Osaka, Japan
  • Saga-shi, Saga, Japan
  • Chuo-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Musashino-shi, Tokyo, Japan
  • Gangnam-gu, Seoul, Korea, Republic of
  • Songpa-gu, Seoul, Korea, Republic of
09

References and documents

Publications

  • Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4. PubMed 27704266 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2009 to primary completion in Jun 2014, 58 months.

Results were first posted in Feb 2019, 4 years 7 months after primary completion.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 58 months is above that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Jul 24, 2009
StartActual
Jul 24, 2009
Primary completionActual
Jun 15, 2014
CompletionActual
Aug 13, 2015
Results first posted
Feb 1, 2019
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00946153
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2009
Start date
Jul 24, 2009
Primary completion
Jun 15, 2014
Completion
Aug 13, 2015
Results posted
Feb 1, 2019
Last update
Feb 1, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion